MENS — Jyong Biotech Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1954488 ·
Taiwan
Last close
$2.17
Market Cap
$161.09M
52W High
$3.00
52W Low
$1.66
ADV30
73,241
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 20,778,000 | 1,175,000 | 45,684,000 |
| Jun 2025 | — | — | — | — | 37,671,000 | 132,000 | 60,143,000 |
| Dec 2024 | — | — | — | — | 6,366,000 | 98,000 | 42,885,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-33,080,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -2,607,000 | -4,671,000 | 20,778,000 | 45,684,000 | — | -3,041,000 |
| Dec 2024 | 0 | -2,056,000 | -3,019,000 | 6,366,000 | 42,885,000 | — | -3,624,000 |
| Dec 2023 | 0 | -2,797,000 | -4,400,000 | 8,248,000 | 42,321,000 | — | -2,601,000 |
| Dec 2022 | 0 | -2,829,000 | -6,630,000 | 8,745,000 | 38,376,000 | — | -2,971,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TTRX | Turn Therapeutics Inc. | $159.66M | $5.36 | — |
| ENLV | Enlivex Ltd. | $164.88M | $0.68 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $165.34M | $4.04 | — |
| PRQR | ProQR Therapeutics N.V. | $165.42M | $1.57 | — |
| SPRO | Spero Therapeutics, Inc. | $165.60M | $2.86 | — |
News headlines (Yahoo Finance, 1h cache)
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
2026-05-15 12:30 · Yahoo
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
2026-04-29 00:00 · Yahoo
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
2026-03-28 00:00 · Yahoo
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongsi
2026-02-13 00:00 · Yahoo
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop
2026-02-10 10:46 · Yahoo
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
2026-01-30 13:30 · Yahoo
Jyong Biotech Responds to Share Price and Volume Movement
2025-12-19 14:00 · Yahoo
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
2025-12-04 13:30 · Yahoo
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
2025-11-24 13:30 · Yahoo
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8
2025-11-21 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.